K Number
K173967
Manufacturer
Date Cleared
2018-02-22

(55 days)

Product Code
Regulation Number
888.3360
Reference & Predicate Devices
Predicate For
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The REMEDY® Acetabular Cup 46mm ID/54mm OD consists of an acetabular cup that is indicated for temporary use (maximum 180 days) as an adjunct to total hip replacement (THR) in skeletally mature patients undergoing a two-stage procedure due to a septic process, and where gentamicin is the most appropriate antibiotic based on the susceptibility pattern of the infecting micro-organism(s).

The REMEDY® Acetabular Cup 46mm ID/54mm OD is positioned into the acetabular cavity following removal of the existing acetabular and femoral components and radical debridement. The device must be combined with REMEDY® Hip Spacer using REMEDY® Modular Head 46 mm. The device is intended for use in conjunction with systemic antimicrobial antibiotic therapy (standard treatment approach to an infection).

The REMEDY® Acetabular Cup 46mm ID/54mm OD is not intended for use for more than 180 days, at which time it must be explanted and a permanent device implanted or another appropriate treatment performed (e.g. resection arthroplasty, etc.).

Device Description

The Remedy® Acetabular Cup is a temporary spacer device available in a single size, intended to be combined with Remedy Hip Spacer using Remedy® Modular Head 46 mm.

The Remedy® Acetabular Cup is sterile, single-use device intended for temporary use (maximum 180 days) as joint replacement. The device is made of fully formed polymethylmethacrylate (PMMA), which is radio-opaque and contains gentamicin. The mass used to fill the molds (the unformed PMMA resin) is prepared from powder and liguid components. The liquid component consists of methylmethacrylate (MMA), N, N dimethylp-toluidine and hydroquinone; the powder component consists of PMMA, barium sulphate, benzoyl peroxide and gentamicin sulphate.

The Remedy® Hip Spacer and Acetabular Cup provide a functional-mechanical mode of action; the system provides patients a temporary implant allowing for a natural range of motion and partial weight-bearing during treatment. The system is designed to preserve soft tissue to prevent further complications, such as muscular contraction, and to facilitate the subsequent joint replacement procedure. The Remedy® Acetabular Cup is protected from bacterial adhesion due to the presence of gentamicin, similar to other spacers devices made from antibiotic loaded PMMA currently on the US market.

AI/ML Overview

The provided text describes a 510(k) premarket notification for a medical device called the "Remedy® Acetabular Cup." This documentation is for regulatory clearance and focuses on demonstrating substantial equivalence to a predicate device, not on proving clinical efficacy or diagnostic performance as one might for an AI/ML medical device.

Therefore, the information required to answer your questions about acceptance criteria, test sets, ground truth establishment, expert adjudication, MRMC studies, and training sets for an AI/ML device is not present in the provided document. The document primarily details:

  • Device Description: What the Remedy® Acetabular Cup is (a temporary acetabular cup spacer with gentamicin).
  • Intended Use: Its temporary use (max 180 days) as an adjunct to total hip replacement in a two-stage procedure due to a septic process.
  • Comparison to Predicate Device: How it is similar and different from its predicate (Remedy® Hip Spacer) in terms of materials, design, and performance characteristics.
  • Performance Data (Non-Clinical): Summaries of sterilization, shelf life, biocompatibility, and mechanical performance testing (static, fatigue, surface roughness, wear, antibiotic elution).

In the context of the provided text, there are no "acceptance criteria" or "study" described that would prove an AI/ML device meets certain performance metrics. The "performance data" referred to in section 8 are bench and lab tests demonstrating the physical and material properties of the implant, not clinical or diagnostic performance evaluated against a ground truth dataset in the way an AI/ML model would be.

To directly answer your request based on the absence of this information in the provided text:

  1. A table of acceptance criteria and the reported device performance:
    • No such table exists for an AI/ML device's performance metrics (e.g., sensitivity, specificity, AUC). The document lists mechanical and material performance attributes, but not against quantitative "acceptance criteria" in a table format relatable to AI.
  2. Sample sized used for the test set and the data provenance:
    • Not applicable/Not provided. There is no test set of patient data for AI model evaluation.
  3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
    • Not applicable/Not provided. Ground truth establishment for an AI/ML model is not mentioned.
  4. Adjudication method for the test set:
    • Not applicable/Not provided.
  5. If a multi reader multi case (MRMC) comparative effectiveness study was done:
    • No. This is a physical implant, not a diagnostic AI tool requiring MRMC studies.
  6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
    • Not applicable.
  7. The type of ground truth used:
    • Not applicable.
  8. The sample size for the training set:
    • Not applicable.
  9. How the ground truth for the training set was established:
    • Not applicable.

Summary of what is provided about "performance data" (non-AI related):

The document states in section 8, "PERFORMANCE DATA":

  • Sterilization and Shelf Life: Validated using international standards. Endotoxins tested via LAL test, meeting <20 EU/device.
  • Biocompatibility: Evaluated based on ISO 10993 and FDA Draft Guidance, finding materials safe and biocompatible.
  • Performance Testing (Mechanical/Material): Included evaluation of static and fatigue performances, surface roughness, device wear, and antibiotic (gentamicin) elution testing. The document states these "demonstrate that the new device is substantially equivalent to the predicate device."

This 510(k) submission is for a physical medical device (an implant), not a software or AI-driven diagnostic or therapeutic device. Therefore, the types of studies and acceptance criteria you're asking about (which are standard for AI/ML medical devices) are not relevant to this specific document.

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains two logos. On the left is the logo for the Department of Health & Human Services, which features a stylized human figure. To the right is the logo for the U.S. Food & Drug Administration (FDA). The FDA logo includes the acronym "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with "ADMINISTRATION" written below in a smaller font.

February 22, 2018

OsteoRemedies LLC % Diane Mandell Horwitz, Ph.D., RAC Regulatory Affairs Consultant Mandell Horwitz Consultants LLC 2995 Steven Martin Drive Fairfax, Virginia 20031

Re: K173967

Trade/Device Name: Remedy® Acetabular Cup Regulation Number: 21 CFR 888.3360 Regulation Name: Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis Regulatory Class: Class II Product Code: KWL, KWY, KWZ Dated: December 28, 2017 Received: December 29, 2017

Dear Dr. Horwitz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);

{1}------------------------------------------------

and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely, Katherine D. Kavlock -S for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.

510(k) Number (if known) K173967

Device Name Remedy® Acetabular Cup

Indications for Use (Describe)

The REMEDY® Acetabular Cup 46mm ID/54mm OD consists of an acetabular cup that is indicated for temporary use (maximum 180 days) as an adjunct to total hip replacement (THR) in skeletally mature patients undergoing a two-stage procedure due to a septic process, and where gentamicin is the most appropriate antibiotic based on the susceptibility pattern of the infecting micro-organism(s).

The REMEDY® Acetabular Cup 46mm OD is positioned into the acetabular cavity following removal of the existing acetabular and femoral components and radical debridement. The device must be combined with REMEDY® Hip Spacer using REMEDY® Modular Head 46 mm. The device is intended for use in conjunction with systemic antimicrobial antibiotic therapy (standard treatment approach to an infection).

The REMEDY® Acetabular Cup 46mm ID/54mm OD is not intended for use for more than 180 days, at which time it must be explanted and a permanent device implanted or another appropriate treatment performed (e.g. resection arthroplasty, etc.).

Type of Use (Select one or both, as applicable)
> Prescription Use (Part 21 CFR 801 Subpart D)Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

GENERAL INFORMATION 1

Submitter and Owner of the 510(k) 1.1

OsteoRemedies LLC 6800 Poplar Avenue Suite 120 Memphis, TN 38138

1.2 Official Correspondent

Diane Mandell Horwitz, PhD, RAC Regulatory Affairs Consultant Mandell Horwitz Consultants, LLC 2995 Steven Martin Drive Fairfax, Virginia 20031

Telephone: (703) 307-2921 E-mail: dmh@mandellhorwitzconsulting.com

1.3 510(k) Number and Devices Subject of this 510(k)

K173967 Remedy® Acetabular Cup

Date of Preparation 1.4

February 4, 2018

NAME OF THE DEVICE AND CLASSIFICATION INFORMATION 2

2.1 Trade/Proprietary Name

Remedy® Acetabular Cup

2.2 Common/Usual Name

Temporary Acetabular Cup Spacer with Gentamicin

2.3 Classification Information

Classification Name:Hip joint femoral (hemi-hip) metalliccemented or uncemented prosthesisHip joint metal/polymer constrained cemented oruncemented prosthesis
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

{4}------------------------------------------------

Classification Regulation:888.3360888.3310
Class:IIII
Product Code(s):KWL - Prosthesis, Hip, Hemi-,Femoral, MetalKWY - Prosthesis, Hip, Hemi-,Femoral, Metal/polymer, Cemented orUncementedKWZ – Prosthesis, Hip,Constrained or Uncemented,Metal/Polymer
Panel:OrthopaedicOrthopaedic

ತೆ PREDICATE DEVICE

The predicate device is as follows:

  • Remedy® Hip Spacer which was cleared originally through 510(k) application K112470.

DEVICE DESCRIPTION ব

The Remedy® Acetabular Cup is a temporary spacer device available in a single size, intended to be combined with Remedy Hip Spacer using Remedy® Modular Head 46 mm.

The Remedy® Acetabular Cup is sterile, single-use device intended for temporary use (maximum 180 days) as joint replacement. The device is made of fully formed polymethylmethacrylate (PMMA), which is radio-opaque and contains gentamicin. The mass used to fill the molds (the unformed PMMA resin) is prepared from powder and liguid components. The liquid component consists of methylmethacrylate (MMA), N, N dimethylp-toluidine and hydroquinone; the powder component consists of PMMA, barium sulphate, benzoyl peroxide and gentamicin sulphate.

The Remedy® Hip Spacer and Acetabular Cup provide a functional-mechanical mode of action; the system provides patients a temporary implant allowing for a natural range of motion and partial weight-bearing during treatment. The system is designed to preserve soft tissue to prevent further complications, such as muscular contraction, and to facilitate the subsequent joint replacement procedure. The Remedy® Acetabular Cup is protected from bacterial adhesion due to the presence of gentamicin, similar to other spacers devices made from antibiotic loaded PMMA currently on the US market.

5 INDICATIONS FOR USE

Below is the indication for use.

The REMEDY® Acetabular Cup 46mm ID/54mm OD consists of an acetabular cup that is indicated for temporary use (maximum 180 days) as an adjunct to total hip replacement (THR) in skeletally mature patients undergoing a two-stage procedure due to a septic process, and where gentamicin is the most appropriate antibiotic based on the susceptibility pattern of the infecting micro-organism(s).

{5}------------------------------------------------

The REMEDY® Acetabular Cup 46mm ID/54mm OD is positioned into the acetabular cavity following removal of the existing acetabular and femoral components and radical debridement. The device must be combined with REMEDY® Hip Spacer using REMEDY® Modular Head 46 mm. The device is intended for use in conjunction with systemic antimicrobial antibiotic therapy (standard treatment approach to an infection).

The REMEDY® Acetabular Cup 46mm ID/54mm OD is not intended for use for more than 180 days, at which time it must be explanted and a permanent device implanted or another appropriate treatment performed (e.g. resection arthroplasty, etc.).

6 COMPARISON OF THE INTENDED USE WITH THE PREDICATE DEVICE

The Remedy® Acetabular Cup and the predicate device are intended to be used in the same surgical procedure (two-stage revision procedure) in the same target patient population, and provide the same primary function of providing patients a temporary hip implant to allow for a natural range of motion and partial weight bearing. Thus, the Remedy® Acetabular Cup has the same intended use as the predicate device.

COMPARISON OF THE TECHNOLOGICAL CHARACTERISTICS WITH THE 7 PREDICATE DEVICE

The Remedy® Acetabular Cup shares many of the same technological characteristics compared to the predicate Remedy® Hip Spacer, including important considerations such as the same materials, same PMMA bone cement formulation including antibiotic concentration, and mechanical performances. The technological characteristics are the same between the proposed device and the predicate device (see table).

Ally Unuvi
CharacteristicsOsteoRemedies LLCRemedy® Acetabular Cup –Subject DeviceOsteoRemedies LLCRemedy® Hip Spacer –Predicate Device (K112470)Comparison
Main MaterialComponentsPolymethylmethacrylate(PMMA)Methylmethacrylate (MMA)Barium SulphatePolymethylmethacrylate(PMMA)Methylmethacrylate (MMA)Barium SulphateSame
Other MaterialComponentsBenzoyl peroxideN,N-Dimethyl-p-toluidineHydroquinoneBenzoyl peroxideN,N-Dimethyl-p-toluidineHydroquinoneSame
AntibioticGentamicin SulphateGentamicin SulphateSame
Inner coreNoneStainless Steel (AISI 316 ESR)Different
Design (shape)CupHead + StemDifferent
Modularity andSizesNone - 1 size for cup to match46 mm head3 heads, 3 stems, offsetadjustmentDifferent
ArticulatingSurfacesPMMA (Remedy acetabular cup)PMMA (Remedy hip spacer)Patient Bone - PMMA (Remedyhip spacer)Different
X-ray VisibilityYesYesSame
Table 1: Summary of Technological Characteristics between the Remedy® Acetabula
Cup and the Predicate Device, the Remedy® Hip Spacer

{6}------------------------------------------------

CharacteristicsOsteoRemedies LLCRemedy® Acetabular Cup –Subject DeviceOsteoRemedies LLCRemedy® Hip Spacer –Predicate Device (K112470)Comparison
Single-use DeviceYesYesSame
Provided SterileYesYesSame
Spacer SterilizationMethodEthylene OxideEthylene OxideSame
Sterility AssuranceLevel (SAL)10-610-6Same
Shelf Life5 years5 yearsSame

The Remedy® Acetabular Cup and the predicate device, the Remedy® Hip Spacer, are intended to be used together to form a total hip implant: this is analogous to the Prostalac Hip System by DePuy Orthopedics, which served as a reference device for this design feature. Both provide total hip temporary spacers with antibiotic-loaded PMMA cement.

8 PERFORMANCE DATA

This 510(k) notification provided performance data to establish the substantial equivalence of the Remedy® Acetabular Cup to the predicate device. The following is a summary of the performance data.

Sterilization and Shelf Life: The devices are sterilized using standard methods and the sterilization cycles have been validated following international standards. The shelf life of the devices has been established through stability studies. The device is tested for endotoxins using the LAL test (gel clot) in conformance with the EP current edition of the test and must meet <20 EU/device.

Biocompatibility: Biocompatibility evaluation has been performed to show the device materials are safe, biocompatible and suitable for their intended use. Both ISO 10993 and FDA Draft Guidance "Use of International Standard ISO 10993, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing within a Risk Management Process' have been taken into account to evaluate the biocompatibility of the device materials.

Performance Testing: Performance testing was performed to characterize the Remedy Acetabular Cup. This testing included the evaluation of the static and fatigue performances, the surface roughness, the device wear and the antibiotic (gentamicin) elution testing.

The performance data demonstrate that the new device is substantially equivalent to the predicate device.

§ 888.3360 Hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis.

(a)
Identification. A hip joint femoral (hemi-hip) metallic cemented or uncemented prosthesis is a device intended to be implanted to replace a portion of the hip joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum. This generic type of device includes designs which are intended to be fixed to the bone with bone cement (§ 888.3027) as well as designs which have large window-like holes in the stem of the device and which are intended for use without bone cement. However, in these latter designs, fixation of the device is not achieved by means of bone ingrowth.(b)
Classification. Class II.